Brazil registered 433 new deaths due to COVID-19 on Monday, bringing the total number of deaths from the disease in the country to 181,835, the Ministry of Health reported.
25,193 new cases of the illness caused by the coronavirus were also notified, for a total of 6,927,145 confirmed infections in the country, according to the ministry.
Sundays and Mondays are typically below-average record days in terms of cases and deaths, based on delays in processing evidence on weekends.
Facing an increase and close to reaching 7 million infected, Brazil is the second country with the highest number of deaths from coronavirus globally, behind the United States, and the third in cases, below the United States and India.
According to the official report, in a nation of just over 210 million inhabitants, almost 6 million from the new SARS-CoV-2 coronavirus have been recovered, which represents 87.4% of the total infected.
The state of Sao Paulo, the most populated in the country with 46 million inhabitants and located in the southeast region, continues to be the region with the most confirmed cases and deaths.
Brazil's Experience with Vaccines
Previously, the National Health Surveillance Agency (Anvisa, regulator) approved the regulations for the release in an "emergency and experimental nature" for the use of possible vaccines, even without having obtained the definitive registration for their commercialization and application.
In a unanimous decision, the Collegiate Directive of the regulatory body indicated that the release, without the definitive endorsement, must be requested directly by the manufacturers and meet the "minimum requirements of safety, quality and efficiency."
However, according to Anvisa, none of the laboratories conducting phase three clinical studies of the four formulas they are testing in Brazil has so far requested such a release.
Vaccines from the Anglo-Swedish laboratory AstraZeneca and the British University of Oxford are currently being tested in the country; that of the Chinese pharmaceutical company Sinovac; the consortium of the American Pfizer in conjunction with the German group BioNTec, and that of the Belgian Janssen, which is part of the Johnson & Johnson conglomerate.
Anvisa also determined that vaccines with authorization for emergency use may not be marketed and their application should only be made through the Unified Health System (SUS), which is the public network.
By current legislation, antigens in Brazil can be definitively released after meeting all the requirements; due to an emergency nature, as it has just been approved, and by a legal authority that gives Anvisa 72 hours to endorse one that has been approved in the United States, Europe, Japan or China.